Showing 1 to 2 of 2 results


Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Progress
56% Bias Score

New Drug Shows Significant Promise in Reducing Breast Cancer Progression
A clinical trial shows that the drug camizestrant reduces breast cancer progression by 52% compared to standard treatments, offering a potential breakthrough in precision medicine by using blood tests to detect treatment resistance early.

New Drug Shows Significant Promise in Reducing Breast Cancer Progression
A clinical trial shows that the drug camizestrant reduces breast cancer progression by 52% compared to standard treatments, offering a potential breakthrough in precision medicine by using blood tests to detect treatment resistance early.
Progress
48% Bias Score
Showing 1 to 2 of 2 results